Skip to content
The Nexus
DossierENTITY

cross-border deals

Coverage of cross-border deals in the Nexus archive.

Earliest in view: Jul 13 · 10:15 UTCMost recent: Jul 13 · 10:15 UTC
Co-mentioned in this coverage
Lan Gongtaoperson2National Medical Products Administrationorganization2AI-powered candidatestopic2innovative drugstopic2Department of Drug Registrationorganization1Chinaplace1
Recent coverage
  • BUSINESSJul 13 · 10:15 UTCSCMP WORLD
    China’s drug industry pivots to AI-powered candidates to drive next wave of deals

    China's drug industry is shifting focus to AI-powered drug candidates to drive future deals, following record US$110 billion in cross-border transactions for innovative drugs in the first half of 2026. China accounts for 30% of globally developed new drugs, ranking second worldwide.

  • BUSINESSJul 13 · 10:15 UTCSCMP CHINA
    China’s drug industry pivots to AI-powered candidates to drive next wave of deals

    China's cross-border deals for innovative drugs reached $110 billion in H1 2026, with the industry now focusing on AI-powered candidates to drive future transactions. China holds 30% of globally developed new drugs, ranking second worldwide, according to Lan Gongtao from the National Medical Products Administration.

cross-border deals · Dossier · The Nexus